Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers - Salomon Tendler; Roberto De Gregorio; Paul Balderes; Alexa L. Michel; Tran T. Hoang; David Bauer; Kathryn M. Tully; Joshua A. Korsen; Ivo C. Lorenz; Abdul G. Khan; Lukas Carter; Olivia Vergnolle; et al. (Proceedings of the National Academy of Sciences, 2026)